Thank you, Mr. Chair.
I'd like to thank you both for your presentations. I think the more we hear, the more complicated things get. Certainly you've given us a different perspective on this. I have lots of questions for both of you.
OECD countries face common challenges in addressing new high-cost specialty drugs used in the treatment of cancer, hepatitis C, pulmonary hypertension, multiple sclerosis, and rare diseases. In a number of countries, these drugs are not affordable or accessible to patients who need them. Conversely, sometimes high-cost medicines do not always deliver high health outcomes.
How are the challenges associated with high-cost specialty drugs addressed in your country? What best practices in this area, from either your country or elsewhere, could Canada consider using or adopting?